Report Information More information from: https ://www.wis eguyreports .com/reports /575866
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Pipeline Review, H1 2016 Report / Search Code: WGR575866
Price
1-user P DF : $ 3500.0
Description:
Publish Date: 28 June, 2016
Site P DF : $ 7000.0
Enterprise P DF : $ 10500.0
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Pipeline Review, H1 2016 Summary Global Markets Direct’s , ‘Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Pipeline Review, H1 2016’, provides in depth analys is on Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted pipeline therapeutics . The report provides comprehens ive information on the Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4), targeted therapeutics , complete with analys is by indications , s tage of development, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type. The report als o covers the des criptive pharmacological action of the therapeutics , its complete res earch and development his tory and lates t news and pres s releas es . Additionally, the report provides an overview of key players involved in Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics development and features dormant and dis continued projects . Global Markets Direct’s report features inves tigational drugs from acros s globe covering over 20 therapy areas and nearly 3,000 indications . The report is built us ing data and information s ourced from Global Markets Direct’s proprietary databas es , company/univers ity webs ites , clinical trial regis tries , conferences , SEC filings , inves tor pres entations and featured pres s releas es from company/univers ity s ites and indus try-s pecific third party s ources . Drug profiles featured in the report undergoes periodic review following a s tringent s et of proces s es to ens ure that all the profiles are updated with the lates t s et of information. Additionally, various dynamic tracking proces s es ens ure that the mos t recent developments are captured on a real time bas is . The report helps in identifying and tracking emerging players in the market and their portfolios , enhances decis ion making capabilities and helps to create effective counter s trategies to gain competitive advantage. Note*: Certain s ections in the report may be removed or altered bas ed on the availability and relevance of data. Scope - The report provides a s naps hot of the global therapeutic lands cape for Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - The report reviews Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics under development by companies and univers ities /res earch ins titutes bas ed on information derived from company and indus try-s pecific s ources - The report covers pipeline products bas ed on various s tages of development ranging from pre-regis tration till dis covery and undis clos ed s tages - The report features des criptive drug profiles for the pipeline products which includes , product des cription, des criptive MoA, R& D brief, licens ing and collaboration details & other developmental activities - The report reviews key players involved in Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics and enlis ts all their major and minor projects - The report as s es s es Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics bas ed on mechanis m of action (MoA), route of adminis tration (RoA) and molecule type - The report s ummarizes all the dormant and dis continued pipeline projects - The report reviews lates t news and deals related to Integrin Alpha 4 (CD49 Antigen
Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics Reas ons to buy - Gain s trategically s ignificant competitor information, analys is , and ins ights to formulate effective R& D s trategies - Identify emerging players with potentially s trong product portfolio and create effective counter-s trategies to gain competitive advantage - Identify and unders tand the targeted therapy areas and indications for Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Identify the us e of drugs for target identification and drug repurpos ing - Identify potential new clients or partners in the target demographic - Develop s trategic initiatives by unders tanding the focus areas of leading companies - Plan mergers and acquis itions effectively by identifying key players and it’s mos t promis ing pipeline therapeutics - Devis e corrective meas ures for pipeline projects by unders tanding Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) development lands cape - Develop and des ign in-licens ing and out-licens ing s trategies by identifying pros pective partners with the mos t attractive projects to enhance and expand bus ines s potential and s cope Contents:
Table of Contents Table of Contents 2 Lis t of Tables 5 Lis t of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha CD49d or ITGA4) Overview 7 Therapeutics Development 8 Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha CD49d or ITGA4) - Products under Development by Stage of Development 8 Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha CD49d or ITGA4) - Products under Development by Therapy Area 9 Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha CD49d or ITGA4) - Products under Development by Indication 10 Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha CD49d or ITGA4) - Pipeline Products Glance 12 Late Stage Products 12 Early Stage Products 13 Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha CD49d or ITGA4) - Products under Development by Companies 14 Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha CD49d or ITGA4) - Therapeutics As s es s ment 17 As s es s ment by Monotherapy/Combination Products 17 As s es s ment by Mechanis m of Action 18 As s es s ment by Route of Adminis tration 19 As s es s ment by Molecule Type 21 Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha CD49d or ITGA4) - Companies Involved in Therapeutics Development 23 Antis ens e Therapeutics Limited 23 Atox Bio Ltd. 24 Biogen, Inc. 25 BioMAS Ltd. 26 Daiichi Sankyo Company, Limited 27 EA Pharma Co Ltd 28 Protagonis t Therapeutics Inc. 29 Takeda Pharmaceutical Company Limited 30 Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha CD49d or ITGA4) - Drug Profiles 31 AB-103 - Drug Profile 31 Product Des cription 31 Mechanis m Of Action 31 R& D Progres s 31 AS-101 - Drug Profile 34 Product Des cription 34 Mechanis m Of Action 34 R& D Progres s 34 ATL-1102 - Drug Profile 36 Product Des cription 36 Mechanis m Of Action 36 R& D Progres s 36 carotegras t - Drug Profile 41 Product Des cription 41 Mechanis m Of Action 41
or or or or or
or or
or
or
R& D Progres s 41 natalizumab - Drug Profile 43 Product Des cription 43 Mechanis m Of Action 43 R& D Progres s 43 PTG-100 - Drug Profile 47 Product Des cription 47 Mechanis m Of Action 47 R& D Progres s 47 Small Molecule to Antagonize Integrin Alpha4 and Beta7 for Inflammatory Bowel Dis eas e - Drug Profile 49 Product Des cription 49 Mechanis m Of Action 49 R& D Progres s 49 Small Molecule to Inhibit VLA-4 for As thma - Drug Profile 50 Product Des cription 50 Mechanis m Of Action 50 R& D Progres s 50 Small Molecules to Antagonize Integrin Alpha4 and Integrin Beta7 for Inflammatory Bowel Dis eas e - Drug Profile 51 Product Des cription 51 Mechanis m Of Action 51 R& D Progres s 51 vedolizumab - Drug Profile 52 Product Des cription 52 Mechanis m Of Action 52 R& D Progres s 52 Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Dormant Projects 57 Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Dis continued Products 62 Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Featured News & Pres s Releas es 63 Jun 01, 2016: Antis ens e provides update on ATL1102 clinical trials 63 May 31, 2016: Biogen Receives Pos itive CHMP Opinion for TYSABRI (Natalizumab) Us e in Highly Active RRMS Patients with Inadequate Res pons e to Prior MS Therapy 63 May 26, 2016: Elan Pharma International Withdraw an application for a change to the marketing authoris ation for Tys abri (natalizumab) 64 May 24, 2016: Takeda Pres ents Analys es From Vedolizumab Data in Ulcerative Colitis at 2016 Diges tive Dis eas e Week Annual Meeting 65 May 17, 2016: Protagonis t Therapeutics to Pres ent New Data on PTG-100 at Diges tive Dis eas e Week 2016 66 Apr 12, 2016: Biogen to Pres ent Data on TYSABRI (Natalizumab) at 2016 AAN Annual Meeting 66 Mar 19, 2016: New Data Pres ented at European Crohn's and Colitis Organis ation Scientific Meeting on Efficacy of Long-Term Vedolizumab Treatment 67 Feb 26, 2016: EMA confirms recommendations to minimis e ris k of brain infection PML with Tys abri 68 Feb 12, 2016: Updated recommendations to minimis e the ris k of the rare brain infection PML with Tys abri 71 Jan 15, 2016: Pharmacovigilance Ris k As s es s ment Committee (PRAC) provides update on ongoing referral on Tys abri 72 Jan 08, 2016: Protagonis t Therapeutics Initiates Phas e 1 Study with Oral Peptide PTG-100 73 Dec 07, 2015: Atox Bio Enrolls Firs t Patient in Phas e 3 Study of Potential Treatment for Necrotizing Soft Tis s ue Infection (Fles h Eating Bacteria) 74 Oct 21, 2015: Biogen Reports Top-Line Res ults from Phas e 3 Study Evaluating Natalizumab in Secondary Progres s ive MS 74 Oct 19, 2015: Takeda Pres ents Vedolizumab Data at the 2015 American College of Gas troenterology Annual Meeting and United European Gas troenterology Week 75 Oct 12, 2015: Antis ens e Therapeutics Provides ATL1102 Early Acces s Program Update 77 Appendix 79 Methodology 79 Coverage 79 Secondary Res earch 79 Primary Res earch 79 Expert Panel Validation 79 Contact Us 79 Dis claimer 80 Lis t of Tables Number of Products under Development for, H1 2016 8 Number of Products under Development by Therapy Area, H1 2016 9 Number of Products under Development by Indication, H1 2016 10 Comparative Analys is by Late Stage Development, H1 2016 12 Comparative Analys is by Early Stage Products , H1 2016 13 Number of Products under Development by Companies , H1 2016 14
Products under Development by Companies , H1 2016 15 Products under Development by Companies , H1 2016 (Contd..1) 16 As s es s ment by Monotherapy/Combination Products , H1 2016 17 Number of Products by Stage and Mechanis m of Action, H1 2016 18 Number of Products by Stage and Route of Adminis tration, H1 2016 20 Number of Products by Stage and Molecule Type, H1 2016 22 Pipeline by Antis ens e Therapeutics Limited, H1 2016 23 Pipeline by Atox Bio Ltd., H1 2016 24 Pipeline by Biogen, Inc., H1 2016 25 Pipeline by BioMAS Ltd., H1 2016 26 Pipeline by Daiichi Sankyo Company, Limited, H1 2016 27 Pipeline by EA Pharma Co Ltd, H1 2016 28 Pipeline by Protagonis t Therapeutics Inc., H1 2016 29 Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 30 Dormant Projects , H1 2016 57 Dormant Projects (Contd..1), H1 2016 58 Dormant Projects (Contd..2), H1 2016 59 Dormant Projects (Contd..3), H1 2016 60 Dormant Projects (Contd..4), H1 2016 61 Dis continued Products , H1 2016 62 Lis t of Figures Number of Products under Development for, H1 2016 8 Number of Products under Development by Therapy Area, H1 2016 9 Number of Products under Development by Top 10 Indication, H1 2016 10 Comparative Analys is by Late Stage Development, H1 2016 12 Comparative Analys is by Early Stage Products , H1 2016 13 As s es s ment by Monotherapy/Combination Products , H1 2016 17 Number of Products by Stage and Mechanis m of Actions , H1 2016 18 Number of Products by Routes of Adminis tration, H1 2016 19 Number of Products by Stage and Routes of Adminis tration, H1 2016 19 Number of Products by Molecule Types , H1 2016 21 Number of Products by Stage and Molecule Type, H1 2016 21
wis eguyreports .com / Phone (US) + 1-646-845-9349 (UK) +44 208 133 9349